The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

被引：0

作者：

Mutlu Hizal

Burak Bilgin

Nail Paksoy

Özgür Açıkgöz

Ahmet Sezer

Mustafa Gürbüz

Naziye Ak

Şebnem Yücel

Murat Ayhan

Cihan Erol

Aykut Demirkıran

Nil Molinas Mandel

Abdallah Shbair

İvo Gökmen

Tuğba Başoğlu

Semra Paydaş

Atike Gökçen Demiray

Yakup İriağaç

Teoman Şakalar

Esra Zeynelgil

Ali Murat Tatlı

Aykut Bahçeci

Deniz Can Güven

Burcu Caner

Alper Can

Ahmet Gülmez

Yusuf Karakaş

Bülent Yalçın

Ahmet Demirkazık

Ahmet Bilici

Adnan Aydıner

Perran Fulden Yumuk

Mehmet Ali Nahit Şendur

机构：

[1] Ankara City Hospital,Department of Medical Oncology

[2] Atatürk Chest Disease and Chest Surgery Research and Education Hospital,Department of Medical Oncology

[3] İstanbul University, Department of Medical Oncology, İstanbul Faculty of Medicine

[4] Medipol University,Department of Medical Oncology

[5] Faculty of Medicine,Department of Medical Oncology

[6] Başkent University,Department of Medical Oncology

[7] Faculty of Medicine,Department of Medical Oncology

[8] Ankara University,Department of Medical Oncology

[9] Faculty of Medicine,Department of Medical Oncology

[10] Yozgat City Hospital,Department of Medical Oncology, Meram Faculty of Medicine

[11] Kartal Lütfi Kırdar City Hospital,Department of Medical Oncology

[12] Yıldırım Beyazıt University Faculty of Medicine,Department of Medical Oncology

[13] Necmeddin Erbakan University,Department of Medical Oncology, Faculty of Medicine

[14] American Hospital,Division of Medical Oncology

[15] Bezmialem University Faculty of Medicine,Department of Medical Oncology

[16] Trakya University,Department of Medical Oncology

[17] Marmara University School of Medicine,Department of Medical Oncology

[18] Çukurova University Faculty of Medicine,Department of Medical Oncology

[19] Pamukkale University Faculty of Medicine,Department of Medical Oncology

[20] Namık Kemal University Faculty of Medicine,Department of Medical Oncology

[21] Necip Fazıl City Hospital,Department of Medical Oncology

[22] Dışkapı Education and Research Hospital,Department of Medical Oncology

[23] Akdeniz University Faculty of Medicine,Department of Medical Oncology

[24] Ersin Arslan Education and Research Hospital,Department of Medical Oncology

[25] Hacettepe University Faculty of Medicine,Department of Medical Oncology

[26] Uludağ University Faculty of Medicine,Department of Medical Oncology

[27] İstinye University Faculty of Medicine,undefined

[28] İnönü University Faculty of Medicine,undefined

[29] Bodrum Acıbadem Hospital,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷

关键词：

Osimertinib; Non-small cell lung cancer; EGFR; T790M; Second line;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1501 / 1508

页数：7

共 50 条

[1] The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
Hizal, Mutlu
Bilgin, Burak
Paksoy, Nail
Acikgoz, Ozgur
Sezer, Ahmet
Gurbuz, Mustafa
Ak, Naziye
Yucel, Sebnem
Ayhan, Murat
Erol, Cihan
Demirkiran, Aykut
Mandel, Nil Molinas
Shbair, Abdallah
Gokmen, Ivo
Basoglu, Tugba
Paydas, Semra
Demiray, Atike Gokcen
Iriagac, Yakup
Sakalar, Teoman
Zeynelgil, Esra
Tatli, Ali Murat
Bahceci, Aykut
Guven, Deniz Can
Caner, Burcu
Can, Alper
Gulmez, Ahmet
Karakas, Yusuf
Yalcin, Bulent
Demirkazik, Ahmet
Bilici, Ahmet
Aydiner, Adnan
Yumuk, Perran Fulden
Sendur, Mehmet Ali Nahit
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (06) : 1501 - 1508
[2] Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
Auliac, Jean Bernard
Perol, Maurice
Planchard, David
Monnet, Isabelle
Wislez, Marie
Doubre, Helene
Guisier, Florian
Pichon, Eric
Greillier, Laurent
Mastroianni, Benedicte
Decroisette, Chantal
Schott, Roland
Le Moulec, Sylvestre
Arrondeau, Jennifer
Cortot, Alexis B.
Geriniere, Laurence
Renault, Aldo
Daniel, Catherine
Falchero, Lionel
Chouaid, Christos
LUNG CANCER, 2019, 127 : 96 - 102
[3] Real-Life Data of Osimertinib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Alfaro Autor, C.
Romero, A.
Calvo De Juan, V.
Franco, F.
Sanchez Romero, E.
Ortiz Cortes, N.
Sanz Moreno, S.
Rodriguez Festa, A.
Serna Blasco, R.
Barquin Del Romo, M.
Provencio, M.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1036 - S1036
[4] Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer
Jean-Bernard Auliac
Karima Saboundji
Michel Andre
Jeannick Madelaine
Gilles Quere
Philippe Masson
Alain Vergnenegre
Régine Lamy
Stéphane Raymond
Anne-Marie Chiappa
Pierre-Alexandre Hauss
Pierre Fournel
Romain Corre
Christos Chouaid
Targeted Oncology, 2019, 14 : 307 - 314
[5] Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer
Auliac, Jean-Bernard
Saboundji, Karima
Andre, Michel
Madelaine, Jeannick
Quere, Gilles
Masson, Philippe
Vergnenegre, Alain
Lamy, Regine
Raymond, Stephane
Chiappa, Anne-Marie
Hauss, Pierre-Alexandre
Fournel, Pierre
Corre, Romain
Chouaid, Christos
TARGETED ONCOLOGY, 2019, 14 (03) : 307 - 314
[6] Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
Peng, Da
Shan, Dongfeng
Dai, Chengcheng
Li, Jie
Wang, Zifan
Huang, Ziyi
Peng, Rui
Zhao, Peng
Ma, Xuezhen
CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2033 - 2039
[7] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
Soejima, Kenzo
Yasuda, Hiroyuki
Hirano, Toshiyuki
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
[8] Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice
Oh, Dong Kyu
Ji, Won Jun
Kim, Woo Sung
Choi, Chang-Min
Yoon, Shin-Kyo
Rho, Jin Kyung
Lee, Jae Cheol
PLOS ONE, 2019, 14 (01):
[9] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
Gao, Xin
Le, Xiuning
Costa, Daniel B.
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
[10] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Zheng, Qiufan
Hong, Shaodong
Huang, Yan
Zhao, Hongyun
Yang, Yunpeng
Hou, Xue
Zhao, Yuanyuan
Ma, Yuxiang
Zhou, Ting
Zhang, Yaxiong
Fang, Wenfeng
Zhang, Li
CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):

← 1 2 3 4 5 →